Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS

• Published in: Endocrine Connections Vol. 10; no. 10; pp. 1243 - 1252
• Main Authors: Cheng, Feifei, Ng, Noel Yat Hey, Tam, Claudia Ha Ting, Zhang, Yuying, Lim, Cadmon King Poo, Jiang, Guozhi, Ng, Alex Chi Wai, Yau, Tiffany Tse Ling, Cheung, Lai Ping, Xu, Aimin, Chan, Juliana C N, Ma, Ronald C W
• Format: Journal Article
• Language: English
• Published: Bristol Bioscientifica Ltd 01.10.2021; Bioscientifica
• Subjects: fgf19; fgf21; lipocalin-2; polycystic ovary syndrome; type 2 diabetes; type 2 diabetes; lipocalin-2; FGF19; polycystic ovary syndrome; FGF21
• ISSN: 2049-3614; 2049-3614
• DOI: 10.1530/EC-21-0082

Women with polycystic ovary syndrome (PCOS) have an increased risk of developing type 2 diabetes. FGF19, FGF21 and lipocalin-2 have emerged as important markers of metabolic risk. This study aims to compare the levels of FGF19, FGF21 and lipocalin-2 between subjects with or without PCOS, and to investigate the relationship between proteins and diabetes progression. In this nested case–control cohort study, 128 Chinese PCOS women and 128 controls were recruited and followed-up. All subjects underwent the oral glucose tolerance test for the evaluation of glycaemic status. Baseline serum protein levels were measured using ELISA. Compared with controls, PCOS subjects had higher levels of FGF19 (P < 0.001) and FGF21 (P = 0.022), but had lower lipocalin-2 (P < 0.001). In total, 20.8% of PCOS and 9.2% of controls developed diabetes over a mean duration of 10.4 ± 1.2 and 11.3 ± 0.5 years, respectively. Logistic regression analyses suggested FGF19 was positively associated with diabetes progression in controls, after adjusting for age, follow-up duration, waist and fasting glucose (P = 0.026, odds ratio (OR) (95% CI): 7.4 (1.3–43.6)), and the positive relationship between FGF21 and diabetes progression in controls was attenuated by adjusting for age and follow-up duration (P = 0.183). Lipocalin-2 was positively correlated with diabetes progression in PCOS group (P = 0.026, OR (95% CI)): 2.5 (1.1–5.6)); however, this became attenuated after adjusting for waist and fasting glucose (P = 0.081). In conclusion, there is differential expression of FGF19, FGF21, and lipocalin-2 in PCOS. The serum level of FGF19, and FGF21 is associated with diabetes progression in women without PCOS, while lipocalin-2 was related to diabetes progression in PCOS women.